Lipid Regulators Market: By Type (Statins (Branded Statins, Statin Combination and Generic Statins), and Non-statins (Fibric-acid derivatives, Bile-acid sequestrants, Ezetimibe, Nicotinic acid derivatives, PCSK9 inhibitors, Other non-statins) By Indication (Hypercholesterolemia, Hypertriglyceridemia, Coronary artery disease, and Other indications) By Route of Administration (Oral and Injectable) By Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online pharmacies) and Geography

Lipid Regulators Market was valued at USD 8,346.1 million in 2023 and is poised to grow at a CAGR of 5.8% during 2024-2030. Lipid regulators are a group of drugs aimed at the therapy of a blood disorder called dyslipidemia, which is characterized by abnormal levels of lipids in the blood: fats, including cholesterol and triglycerides. The main goal of lipid regulators is to reduce the amount of low-density lipoprotein cholesterol and increase the level of high-density lipoprotein cholesterol in the organism. These, amongst others, include statins, fibrates, niacin, and bile acid sequestrants. These are very essential drugs in the prevention of cardiovascular diseases such as heart attack and stroke, normally instigated by large amounts of cholesterol in the blood.

The increasing incidence of CVDs globally, driven by factors such as poor diet, sedentary lifestyles, and obesity, is a major driver for the lipid regulators market. High cholesterol levels are a significant risk factor for CVDs, leading to greater demand for lipid-regulating drugs. According to the American Heart Association, nearly half of all adults in the U.S. (approximately 121.5 million) have some form of cardiovascular disease. This number has been steadily increasing due to factors like obesity, hypertension, and diabetes. However, the use of lipid regulators, particularly statins, is often associated with side effects such as muscle pain, liver damage, and an increased risk of diabetes, which can lead to patient non-compliance and limit market growth.Moreover, there is ongoing research into novel lipid-lowering agents, such as PCSK9 inhibitors, which offer potent cholesterol-lowering effects with fewer side effects. These new therapies present significant growth opportunities in the market.

Lipid Regulators Market Key Developments:

• In July 2023: The U.S. FDA expanded the indication for Leqvio to treat adults with high LDL-C and at risk for heart disease this will raise its product offerings and revenue growth.
• In May, 2022: Sun Pharmaceutical Industries Ltd. introduced Brillo in May 2022. This product helps reduce low-density lipoprotein (LDL) levels via bempedoic acid. The strategic step below contributed to expansion in the product segment as well as the top line for the company.